Biotech · Private company · Cambridge, MA, US
GentiBio, Inc
Track this companyFree. Adds GentiBio, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials22 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- GNTI-122Phase 1 · Type 1 Diabetes (T1D)ClinicalTrials.gov · fetched Nov 12, 2026
- blood draw or cheek swabDiabetes Mellitus, Type IClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Study of GNTI-122 in Adults Recently Diagnosed With T1DPHASE1 · RECRUITING · started Sep 3, 2025ClinicalTrials.gov NCT06919354 · fetched Nov 12, 2026
- HLA Demographics Study in Adults With Type 1 DiabetesRECRUITING · started Jun 6, 2025ClinicalTrials.gov NCT06860516 · fetched Nov 12, 2026
NIH awards5
- Engineered Tissue Treg Therapy for the Treatment of ALSFiscal year 2026 · $320KNIH RePORTER 1R43NS149828-01 · fetched Nov 12, 2026
- An allogeneic and gut specific Engineered T regulatory cell therapy for the treatment of Inflammatory Bowel DiseaseFiscal year 2026 · $1.1MNIH RePORTER 1R44DK148134-01 · fetched Nov 12, 2026
- GNTI-148: an allogeneic islet-specific engineered Treg for treating T1DFiscal year 2026 · $1.1MNIH RePORTER 1R44DK148168-01 · fetched Nov 12, 2026
- Development of Tissue Engineered Tregs as a Treatment for Acute Ischemic StrokeFiscal year 2026 · $1.2MNIH RePORTER 5R44NS145848-02 · fetched Nov 12, 2026
- Development of Tissue Engineered Tregs as a Treatment for Acute Ischemic StrokeFiscal year 2025 · $1.2MNIH RePORTER 1R44NS145848-01 · fetched Nov 12, 2026